CJC-1295 (With DAC) Dosage Guide for Growth Hormone Research

CJC-1295 with DAC dosage for growth hormone research is a widely discussed topic in peptide science, particularly in studies focused on hormone optimization, recovery, and body composition. CJC-1295 (With DAC) is a long-acting analog of growth hormone-releasing hormone (GHRH) designed to stimulate sustained release of growth hormone (GH) over an extended period.

The addition of DAC (Drug Affinity Complex) significantly extends the peptide’s half-life, allowing for less frequent dosing compared to shorter-acting GHRH peptides. This makes it especially valuable in structured research protocols where consistent GH elevation is desired.

In this guide, we will explore CJC-1295 with DAC dosage for growth hormone research, including its mechanism of action, usage protocols, benefits, cycle structure, and safety considerations.

CJC-1295 with DAC Dosage for Growth Hormone Research Guide

What is CJC-1295 (With DAC)?

CJC-1295 (With DAC) is a synthetic peptide designed to stimulate the natural production of growth hormone.

Key Characteristics:

  • Long-acting GHRH analog
  • Extended half-life due to DAC
  • Promotes sustained GH release
  • Supports IGF-1 elevation

With DAC vs Without DAC

  • With DAC: Long-acting, weekly dosing
  • Without DAC: Short-acting, multiple daily doses

The DAC version is preferred in research requiring stable GH levels over time.

How CJC-1295 With DAC Works (Mechanism of Action)

CJC-1295 stimulates the pituitary gland to release growth hormone.

Key Actions:

  • Increases GH secretion
  • Elevates IGF-1 levels
  • Enhances protein synthesis pathways
  • Supports recovery and metabolic processes

Unlike direct GH administration, it works through the body’s natural hormone signaling system.

CJC-1295 With DAC Dosage for Growth Hormone Research

When discussing CJC-1295 with DAC dosage for growth hormone research, weekly dosing protocols are typically used due to its extended half-life.

Standard Research Dosage

  • Typical Range: 1 mg – 2 mg per week

Weekly Usage Protocol

  • Administered once or twice per week
  • Maintain consistent schedule

Advanced Protocol

  • Split dose into:
    • 2 injections per week
  • Provides more stable GH release

Cycle Duration

  • Short Cycle: 6 weeks
  • Standard Cycle: 8–12 weeks
  • Extended Research: 12–16 weeks

Daily vs Weekly vs Monthly Use

Daily Use:

  • Not required

Weekly Use:

  • Standard and most effective

Monthly Cycles:

  • Structured long-term protocols

CJC-1295 in Growth Hormone Research

CJC-1295 is widely studied for its ability to enhance GH and IGF-1 levels.

Potential Research Benefits:

  • Increased growth hormone levels
  • Improved recovery markers
  • Enhanced fat metabolism
  • Support for lean tissue development

CJC-1295 for IGF-1 and Recovery

By increasing GH, CJC-1295 indirectly boosts IGF-1 levels.

Observed Research Areas:

  • Tissue repair
  • Muscle recovery pathways
  • Sleep-related GH cycles
  • Hormonal balance

Benefits of CJC-1295 (With DAC) (Research Perspective)

1. Sustained GH Release

Provides long-lasting hormone stimulation.

2. Increased IGF-1 Levels

Supports anabolic and recovery pathways.

3. Reduced Injection Frequency

Weekly dosing improves protocol simplicity.

4. Enhanced Recovery Support

Improves tissue repair and regeneration.

5. Natural Hormone Stimulation

Works through physiological pathways.

CJC-1295 Cycle Structure

Phase Duration Table
PhaseDuration
Initiation2 weeks
Active6–10 weeks
Rest2–4 weeks

Possible Side Effects

CJC-1295 may produce mild effects in research settings.

Potential Effects:

  • Injection site irritation
  • Water retention
  • Mild headaches
  • Flushing sensation

Risk Management

  • Use moderate dosing
  • Maintain weekly consistency
  • Monitor hormone response
  • Avoid excessive cycles

Stacking CJC-1295 in Research Protocols

CJC-1295 is often studied alongside other peptides.

Common Research Pairings:

  • GHRP peptides (for synergistic GH release)
  • Recovery compounds
  • Metabolic regulators

Storage and Handling

  • Store in a refrigerator (2–8°C)
  • Protect from light
  • Do not freeze
  • Use sterile reconstitution methods

FAQs

Still have questions? We’re here to help!

Contact Us
1. What is the ideal CJC-1295 with DAC dosage?

Most research protocols use 1–2 mg per week.

2. Is CJC-1295 taken daily?

No, it is typically administered weekly.

3. How long should a cycle last?

Usually 8–12 weeks, followed by a break.

4. Does CJC-1295 increase growth hormone?

Yes, it stimulates natural GH release.

5. What is the benefit of DAC?

DAC extends the peptide’s half-life, allowing less frequent dosing.

Shop GLP-1 Research Peptides

Veteran-owned, US-based supplier. Third-party lab-tested with COAs and same-day US shipping. For laboratory research use only — not for human or veterinary consumption.

Shop research-grade CJC-1295 (with DAC) — third-party tested with COA →

For laboratory and research use only. This article summarizes published scientific literature for informational purposes. It is not intended for human or veterinary use, and nothing here is medical advice or a dosing recommendation.

Research References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. Link
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PubMed
  3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PubMed

Written by Jay Cipollone, Founder & Research Lead, MyGLP1Store — a veteran-owned, U.S.-based research-peptide supplier with third-party lab testing and published certificates of analysis (COAs).